Is Everything a Challenge for Multiple Sclerosis patients? Nonverbal Semantic Memory Performance in Iranian Relapsing-Remitting Multiple Sclerosis Patients

被引:0
|
作者
Yazdani, Sara [1 ]
Sharifi, Shahla [1 ]
Foroughipour, Mohsen [2 ]
Gol, Atiyeh Kamyabi [1 ]
机构
[1] Ferdowsi Univ Mashhand, Linguist Dept, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Neurol Dept, Gaem Hosp, Mashhad, Razavi Khorasan, Iran
来源
BANGLADESH JOURNAL OF MEDICAL SCIENCE | 2021年 / 20卷 / 02期
关键词
nonverbal information; semantic memory; Multiple sclerosis; Iran; COGNITIVE IMPAIRMENT; INFORMATION; NEURODEGENERATION; DEMYELINATION; DEMENTIA; DEFICITS;
D O I
10.3329/bjms.v20i2.51554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The objective of the current study was to evaluate the nonverbal semantic memory performance of MS patients and compare it with their healthy counterparts. Materials and methods: In this study, 70 patients with definite relapsing-remitting multiple selerosis(15 men and 55 women) and 70 healthy individuals of comparable demographics (age, gender, and education) from patients' relatives and family members were selected based on convenient sampling. The patients recruited for this study were divided into two groups based on their Montreal Cognitive Assessment (MoCA) scores. The first group of patients (MS1) with MoCA scores of 18-25, and the MoCA scores of the second group (MS2) ranged from 10 -17. All of the participants were right-handed, originally born in Mashhad, Iran, and native speakers of Persian. To assess the nonverbal semantic memory performance of the participants, the picture version of The Camel and Cactus Test (CCT) was selected and administered from the Cambridge Semantic Memory battery test. Results: The results revealed that there was no significant difference between the MS1 and the Healthy Controls group in living and man-made variables, while MS2 performed significantly different compared to other groups in these variables. The results also showed that all three groups of participants performed significantly different from each other in reaction time variable. Conclusion: The findings showed that cognitive impairment in multiple sclerosis patients did not affect their nonverbal semantic memory performance, however, it had an impact on their reaction time.
引用
收藏
页码:390 / 395
页数:6
相关论文
共 50 条
  • [41] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [42] Neuropsychological rehabilitation in patients with relapsing-remitting multiple sclerosis: a systematic review
    Redero, Daniel
    Lazaro, Esther
    Vazquez, Natalia
    Soria, Cristina
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,
  • [43] Reasons for switching immunomodulatory therapy in patients with relapsing-remitting multiple sclerosis
    Popiel, Malgorzata
    Bartosik-Psujek, Halina
    AKTUALNOSCI NEUROLOGICZNE, 2021, 21 (01): : 3 - 8
  • [44] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [45] T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients
    Achiron, A
    Lavie, G
    Kishner, I
    Stern, Y
    Sarova-Pinhas, I
    Ben-Aharon, T
    Barak, Y
    Raz, H
    Lavie, M
    Barliya, T
    Faibel, M
    Cohen, IR
    Mandel, M
    CLINICAL IMMUNOLOGY, 2004, 113 (02) : 155 - 160
  • [46] INTENSIVE CIRCUIT CLASS THERAPY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kocica, Jan
    Kolcava, Jan
    Sladeckova, Michaela
    Stourac, Pavel
    Vlckova, Eva
    Dosbaba, Filip
    Kratochvilova, Jitka
    Bednarik, Josef
    JOURNAL OF REHABILITATION MEDICINE, 2022, 54
  • [47] New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
    Fox, Edward J.
    Rhoades, Robert W.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 : S11 - S19
  • [48] Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis
    Langdon, Dawn W.
    Tomic, Davorka
    Penner, Iris-Katharina
    Calabrese, Pasquale
    Cutter, Gary
    Haering, Dieter A.
    Dahlke, Frank
    Kappos, Ludwig
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (12) : 4135 - 4145
  • [49] New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients
    Wagner, S
    Adams, HP
    Sobel, DF
    Slivka, LS
    Sipe, JC
    Romine, JS
    Koziol, JA
    EUROPEAN NEUROLOGY, 2000, 43 (04) : 194 - 200
  • [50] The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis
    Kotov, S. V.
    Fedorova, S. I.
    Yakushina, T. I.
    Lizhdvoy, V. Yu
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 74 - 78